1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Bovine Blood Plasma Derivatives Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Bovine Blood Plasma Derivatives Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Bovine Blood Plasma Derivatives Market Analysis and Forecast, by Derivative Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Derivative Type, 2017–2031
6.3.1. Immunoglobulin
6.3.2. Fibrinogen
6.3.3. Bovine Serum Albumin
6.3.4. Fetal Bovine Serum
6.3.5. Thrombin
6.3.6. Transferrin
6.3.7. Newborn Calf Serum
6.3.8. Others
6.4. Market Attractiveness Analysis, by Derivative Type
7. Global Bovine Blood Plasma Derivatives Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Pharmaceutical Industry
7.3.2. Diagnostics Industry
7.3.3. Cell Culture/ Biotechnology
7.3.4. Research and Development
7.3.5. Food Industry
7.3.6. Cosmetic Industry
7.3.7. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Bovine Blood Plasma Derivatives Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Bovine Blood Plasma Derivatives Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Derivative Type, 2017–2031
9.3.1. Immunoglobulin
9.3.2. Fibrinogen
9.3.3. Bovine Serum Albumin
9.3.4. Fetal Bovine Serum
9.3.5. Thrombin
9.3.6. Transferrin
9.3.7. Newborn Calf Serum
9.3.8. Others
9.4. Market Value Forecast, by Application, 2017–2031
9.4.1. Pharmaceutical Industry
9.4.2. Diagnostics Industry
9.4.3. Cell Culture/ Biotechnology
9.4.4. Research and Development
9.4.5. Food Industry
9.4.6. Cosmetic Industry
9.4.7. Others
9.5. Market Value Forecast, by Country, 2017–2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Derivative Type
9.6.2. By Application
9.6.3. By Country
10. Europe Bovine Blood Plasma Derivatives Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Derivative Type, 2017–2031
10.3.1. Immunoglobulin
10.3.2. Fibrinogen
10.3.3. Bovine Serum Albumin
10.3.4. Fetal Bovine Serum
10.3.5. Thrombin
10.3.6. Transferrin
10.3.7. Newborn Calf Serum
10.3.8. Others
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Pharmaceutical Industry
10.4.2. Diagnostics Industry
10.4.3. Cell Culture/ Biotechnology
10.4.4. Research and Development
10.4.5. Food Industry
10.4.6. Cosmetic Industry
10.4.7. Others
10.5. Market Value Forecast, by Country/Sub-region, 2017–2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Derivative Type
10.6.2. By Application
10.6.3. By Country/Sub-region
11. Asia Pacific Bovine Blood Plasma Derivatives Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Derivative Type, 2017–2031
11.3.1. Immunoglobulin
11.3.2. Fibrinogen
11.3.3. Bovine Serum Albumin
11.3.4. Fetal Bovine Serum
11.3.5. Thrombin
11.3.6. Transferrin
11.3.7. Newborn Calf Serum
11.3.8. Others
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Pharmaceutical Industry
11.4.2. Diagnostics Industry
11.4.3. Cell Culture/ Biotechnology
11.4.4. Research and Development
11.4.5. Food Industry
11.4.6. Cosmetic Industry
11.4.7. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Derivative Type
11.6.2. By Application
11.6.3. By Country/Sub-region
12. Latin America Bovine Blood Plasma Derivatives Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Derivative Type, 2017–2031
12.3.1. Immunoglobulin
12.3.2. Fibrinogen
12.3.3. Bovine Serum Albumin
12.3.4. Fetal Bovine Serum
12.3.5. Thrombin
12.3.6. Transferrin
12.3.7. Newborn Calf Serum
12.3.8. Others
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Pharmaceutical Industry
12.4.2. Diagnostics Industry
12.4.3. Cell Culture/ Biotechnology
12.4.4. Research and Development
12.4.5. Food Industry
12.4.6. Cosmetic Industry
12.4.7. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Derivative Type
12.6.2. By Application
12.6.3. By Country/Sub-region
13. Middle East & Africa Bovine Blood Plasma Derivatives Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Derivative Type, 2017–2031
13.3.1. Immunoglobulin
13.3.2. Fibrinogen
13.3.3. Bovine Serum Albumin
13.3.4. Fetal Bovine Serum
13.3.5. Thrombin
13.3.6. Transferrin
13.3.7. Newborn Calf Serum
13.3.8. Others
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Pharmaceutical Industry
13.4.2. Diagnostics Industry
13.4.3. Cell Culture/ Biotechnology
13.4.4. Research and Development
13.4.5. Food Industry
13.4.6. Cosmetic Industry
13.4.7. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Derivative Type
13.6.2. By Application
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Merck KGaA
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. LAMPIRE Biological Laboratories, Inc.
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Proliant Health & Biologicals
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Rocky Mountain Biologicals
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Bovogen Biologicals Pty Ltd.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Thermo Fisher Scientific, Inc.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Kraeber & Co GmbH
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Auckland BioSciences Ltd.
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Lake Immunogenics, Inc.
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
